Targeting KRAS in pancreatic adenocarcinoma:Progress in demystifying the holy grail  

作　　者：Ahmed Elhariri Ahmed Alhaj Daniel Ahn Mohamad Bassam Sonbol Tanios Bekaii-Saab Christina Wu Michael Scott Rutenberg John Stauffer Jason Starr Umair Majeed Jeremy Jones Mitesh Borad Hani Babiker 

机构地区：[1]Division of Hematology-Oncology,Department of Medicine,Mayo Clinic Florida,Mayo Clinic Cancer Center,Jacksonville,FL 32224,United States [2]Division of Hematology-Oncology,Department of Medicine,Mayo Clinic Arizona,Mayo Clinic Cancer Center,Phoenix,AZ 85054,United States [3]Department of Radiation-Oncology,Mayo Clinic Florida,Mayo Clinic Cancer Center,Jacksonville,FL 32224,United States [4]Department of Surgical Oncology,Hepatopancreatobiliary Surgery,Mayo Clinic Florida,Jacksonville,FL 32224,United States

出　　处：《World Journal of Clinical Oncology》2023年第8期285-296,共12页世界临床肿瘤学杂志（英文版）

摘　　要：Pancreatic cancer(PC)remains one of the most challenging diseases,with a very poor 5-year overall survival of around 11.5%.Kirsten rat sarcoma virus(KRAS)mutation is seen in 90%-95%of PC patients and plays an important role in cancer cell proliferation,differentiation,metabolism,and survival,making it an essential mutation for targeted therapy.Despite extensive efforts in studying this oncogene,there has been little success in finding a drug to target this pathway,labelling it for decades as“undruggable”.In this article we summarize some of the efforts made to target the KRAS pathway in PC,discuss the challenges,and shed light on promising clinical trials.

关 键 词：Kirsten rat sarcoma virus Targeted therapy Pancreatic cancer Drug resistance Next generation sequencing Clustered regularly interspaced short palindromic repeats 

分 类 号：R576[医药卫生—消化系统] R735.9[医药卫生—内科学]